It’s been an eventful summer. We formally launched the Verantos Evidence Platform, which is live and in use with top pharma. It is also the implementation platform for the FDA-sponsored TRUST demonstration project. Inc Magazine recognized Verantos’ strong growth, ranking us #224 in the nation across all privately held, independent companies and markets. We continue to be noticed in industry trade magazines, most recently in Life Science Leader.

Company News


Verantos logo

Verantos launches platform for high-validity real-world evidence

Verantos, the global leader in high-validity real-world evidence (RWE), today announced the launch of the Verantos Evidence Platform. The Verantos Evidence Platform provides life sciences organizations with the ability to generate RWE that meets the highest evidentiary standards, including those defined by Food and Drug Administration (FDA) draft guidance.

Verantos reached #224 on the 2022 Inc 5000 list

Inc 5000 ranks Verantos #224 for 2022

Verantos ranked in the top 4% fastest growing, privately held companies in America. The ranking recognizes Verantos’ strong growth over recent years and is a testament to the growing life science demand for high-validity RWE.

Life Science Leader

Life Science Leader features Verantos advice on engaging with DC

Life Science Leader published a byline by Verantos on participating in the legislative process. “In the role of an expert, the goal is to provide expertise that is otherwise not readily available to have your voice and perspective heard.” Verantos leadership has participated in Obama and Biden advisory committees and testified before Congress on the 21st Century Cures Initiative.

Want to receive this newsletter in your inbox?